{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CliniMACS%C2%AE+CD34+Reagent+System", "query": { "intervention": "CliniMACS® CD34 Reagent System" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CliniMACS%C2%AE+CD34+Reagent+System&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T17:12:05.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01745913", "title": "Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Acute Lymphocytic Leukemia", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CliniMACS® CD34 Reagent System", "type": "DEVICE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "DRUG" }, { "name": "Double Umbilical Cord Blood Transplantation", "type": "PROCEDURE" }, { "name": "Haplo-Identical Cord Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "DRUG", "PROCEDURE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-10-26", "completion_date": "2015-04-29", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01745913" }, { "nct_id": "NCT02026934", "title": "CliniMACS® CD34+ Reagent System for Expanded Access Use", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Graft-Versus-Host Disease(GVHD)", "Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells", "Graft Failure", "Delayed Graft Function" ], "interventions": [ { "name": "CliniMACS CD34 Reagent System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Joseph Antin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2013-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-11-21", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02026934" }, { "nct_id": "NCT04804891", "title": "Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intestinal Transplantation" ], "interventions": [ { "name": "Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2021-10-22", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04804891" }, { "nct_id": "NCT03538899", "title": "Autologous Gene Therapy for Artemis-Deficient SCID", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "AProArt-CD34", "type": "DRUG" }, { "name": "CliniMACS® CD34 Reagent System cell sorter device", "type": "DEVICE" }, { "name": "Busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": null, "sex": "ALL", "summary": "2 Months and older" }, "enrollment_count": 24, "start_date": "2018-05-31", "completion_date": "2038-06", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538899" }, { "nct_id": "NCT03717480", "title": "Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "ClinicMACs", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2020-01-21", "completion_date": "2021-04-26", "has_results": true, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03717480" }, { "nct_id": "NCT01810588", "title": "Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "CliniMACS® CD34 Reagent System", "type": "DEVICE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "anti-thymocyte globulin (rabbit)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2012-10-16", "completion_date": "2026-03-24", "has_results": true, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01810588" }, { "nct_id": "NCT04337515", "title": "A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Graft Vs Host Disease", "Graft-versus-host-disease" ], "interventions": [ { "name": "CliniMacs®", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Christopher Dvorak", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 90, "start_date": "2019-12-19", "completion_date": "2035-01-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04337515" }, { "nct_id": "NCT05508009", "title": "Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SIOD", "Cystinosis", "FSGS", "SLE Nephritis", "CKD Stage 4" ], "interventions": [ { "name": "Cyclophosphamide 1200 mg/Kg", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 100 mg/Kg", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "ATG", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System", "type": "DEVICE" }, { "name": "Kidney Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE", "PROCEDURE" ], "sponsor": "Alice Bertaina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 12, "start_date": "2023-01-10", "completion_date": "2034-10", "has_results": false, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05508009" }, { "nct_id": "NCT06986382", "title": "Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System", "type": "DEVICE" }, { "name": "Prednisone/Methylprenisolone", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 14, "start_date": "2025-07", "completion_date": "2040-07", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06986382" }, { "nct_id": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Acute Myelogenous Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Juvenile Myelomonocytic Leukemia (JMML)", "Acute Lymphoblastic Leukemia (ALL)", "Lymphoma (Hodgkin's and Non-Hodgkin's)" ], "interventions": [ { "name": "CliniMACS CD34+ Reagent System", "type": "DEVICE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Diane George", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 14, "start_date": "2013-06-03", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-21T17:12:05.877Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061800" } ] }